measles, mumps & rubella combined vaccine (MMR)

From Aaushi
Jump to navigation Jump to search
[1][2][3][4][5][6][7][8][9][10][11][12][13][14][15]

Indications

* MMR vaccine associated with less severe COVID-19[14]

Contraindications

Caution:

pregnancy-category -

safety in lactation ?

Dosage

Children > 15 months & adults: 0.5 mL SC

  • CDC recommends all children get two doses of MMR starting with 1st dose at 12-15 months of age, the 2nd dose at 4-6 years of age

Injection: 1000 TCID50 of measles & rubella vaccine 5000 TCID of mumps vaccine

Pharmacokinetics

  • 2-4 weeks for MUMPS protection after vaccination
  • duration of action is unknown, but may last 12-23 years
  • elimination: liver

Adverse effects

Drug interactions

Test interactions

  • temporary suppression of TB skin test reactivity with onset 3 days after vaccine administration

Mechanism of action

More general terms

Additional terms

References

  1. ↑ Kaiser Permanente Northern California Regional Drug Formulary, 1998
  2. ↑ Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 871
  3. ↑ Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  4. ↑ 4.0 4.1 Journal Watch 22(24):185, 2002 Madsen KM el al, N Engl J Med 347:1477, 2002
  5. ↑ 5.0 5.1 Journal Watch 24(16):127-128, 2004 Vestergaard M, Hviid A, Madsen KM, Wohlfahrt J, Thorsen P, Schendel D, Melbye M, Olsen J. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA. 2004 Jul 21;292(3):351-7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15265850
  6. ↑ MUMPS Advisory #1, secretary of health
  7. ↑ 7.0 7.1 Ogbuanu IU et al Impact of a Third Dose of Measles-Mumps-Rubella Vaccine on a Mumps Outbreak Pediatrics. Nov 5, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23129075 <Internet> http://pediatrics.aappublications.org/content/early/2012/10/30/peds.2012-0177.abstract
    Cardemil CV, Dahl RM, James L et al Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med 2017; 377:947-956. September 7, 2017. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28877026 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1703309
  8. ↑ 8.0 8.1 McLean HQ et al Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps, 2013: Summary Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. June 14, 2013 / 62(RR04);1-34 http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm
  9. ↑ 9.0 9.1 Heijstek MW et al Effects of the Live Attenuated Measles-Mumps-Rubella Booster Vaccination on Disease Activity in Patients With Juvenile Idiopathic Arthritis. A Randomized Trial. JAMA. 2013;309(23):2449-2456 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23780457 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1697965
  10. ↑ 10.0 10.1 Hambidge SJ et al Timely Versus Delayed Early Childhood Vaccination and Seizures. Pediatrics. May 19, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24843064 <Internet> http://pediatrics.aappublications.org/content/early/2014/05/14/peds.2013-3429.abstract
  11. ↑ 11.0 11.1 11.2 Maglione MA et al Safety of Vaccines Used for Routine Immunization of US Children: A Systematic Review. Pediatrics; published online July 1, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25086160 <Internet> http://pediatrics.aappublications.org/content/early/2014/06/26/peds.2014-1079.full.pdf+html
    Byington CL Vaccines: Can Transparency Increase Confidence and Reduce Hesitancy? Pediatrics; published online July 1, 2014 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25086161 <Internet> http://pediatrics.aappublications.org/content/early/2014/06/26/peds.2014-1494.full.pdf+html
  12. ↑ 12.0 12.1 Jain A, MarshallJ, Buikema A et al Autism Occurrence by MMR Vaccine Status Among US Children With Older Siblings With and Without Autism. JAMA. 2015;313(15):1534-1540 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25898051 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=2275444
    King BH Promising Forecast for Autism Spectrum Disorders. JAMA. 2015;313(15):1518-1519 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25898047 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=2275426
  13. ↑ 13.0 13.1 Hviid A, Hansen JV, Frisch M, Melbye M. Measles, Mumps, Rubella Vaccination and Autism: A Nationwide Cohort Study. Ann Intern Med. 2019. Mar 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30831578 https://annals.org/aim/article-abstract/2727726/measles-mumps-rubella-vaccination-autism-nationwide-cohort-study
    Omer SB, Yildirim I. Further Evidence of MMR Vaccine Safety: Scientific and Communications Considerations. Ann Intern Med. 2019. Mar 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/30831577 https://annals.org/aim/article-abstract/2727208/further-evidence-mmr-vaccine-safety-scientific-communications-considerations
  14. ↑ 14.0 14.1 14.2 Reuters Staff MMR Vaccine Linked With Less Severe COVID-19. Medscape - Nov 20, 2020. https://www.medscape.com/viewarticle/941391
  15. ↑ 15.0 15.1 Medical Knowledge Self Assessment Program (MKSAP) 19 American College of Physicians, Philadelphia 2022
Retrieved from "https://aaushi.info/w/index.php?title=A6107&oldid=1173346"